RT Book, Section A1 Bartelink, Harry A1 Meijnen, Philip A1 Straver, Marieke A1 Rutgers, Emiel A2 Kuerer, Henry M. SR Print(0) ID 6413009 T1 Chapter 45. The EORTC Experience: From DCIS to Locally Advanced Breast Cancer T2 Kuerer's Breast Surgical Oncology YR 2010 FD 2010 PB The McGraw-Hill Companies PP New York, NY SN 978-0-07-160178-8 LK accesssurgery.mhmedical.com/content.aspx?aid=6413009 RD 2024/04/18 AB The European Organization for Research and Treatment of Cancer (EORTC) Breast Group and the Radiotherapy Group successfully completed several clinical trials that included thousands of patients with the goal of improving outcomes by evaluating different approaches in the locoregional treatment of breast cancer. These trials addressed the need for and feasibility of alternative or more aggressive treatment regimens and new ways to predict therapeutic outcomes. For ductal carcinoma in situ (DCIS), the contribution of radiotherapy in achieving local control was examined. For stage I and II breast cancer, mastectomy was compared with breast-conserving therapy. This was followed by a trial in which 2 different dose levels of irradiation were tested (ie, is an extra boost dose required after whole-breast irradiation?). Reduction of morbidity is the aim of the After Mapping of the Axilla Radiotherapy or Surgery (AMAROS) trial comparing axillary lymph node dissection with axillary irradiation in patients with proven axillary metastases in the sentinel nodes. For locally advanced breast cancer, the contribution of hormonal therapy and chemotherapy was investigated. Finally, the possibility of predicting treatment outcomes and therefore individualizing treatment regimens is explored in ongoing trials incorporating genomic profiles. A selection of the EORTC breast cancer trials is presented in this overview, followed by some of the new studies and suggestions for future research.